779353-65-0 Usage
Description
3-((5-chloro-3-ethylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide is a complex chemical compound with a unique structure that features a pyridine ring with a nitrogen atom, a pyrazole ring with a chlorine atom and an ethyl group, and a pyrimidine ring with an amino group and an ethyl group. Additionally, it contains a pyridine 1-oxide functional group. 3-((5-chloro-3-ethylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide's structure suggests it may possess biological activity, making it a potential candidate for further development as a drug for various medical conditions.
Uses
Used in Pharmaceutical Industry:
3-((5-chloro-3-ethylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide is used as a potential drug candidate for the development of new medications due to its unique structure and possible biological activity. Its specific application reason is not provided in the materials, but its potential use in the pharmaceutical industry is based on the assumption that its structure may confer beneficial properties for treating certain medical conditions.
Since the provided materials do not specify particular applications or industries for 3-((5-chloro-3-ethylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide, the above use is a general statement based on the compound's potential pharmaceutical relevance. Further research and development would be required to determine its exact applications and efficacy in specific medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 779353-65-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,7,9,3,5 and 3 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 779353-65:
(8*7)+(7*7)+(6*9)+(5*3)+(4*5)+(3*3)+(2*6)+(1*5)=220
220 % 10 = 0
So 779353-65-0 is a valid CAS Registry Number.
779353-65-0Relevant articles and documents
Discovery of dinaciclib (SCH 727965): A potent and selective inhibitor of cyclin-dependent kinases
Paruch, Kamil,Dwyer, Michael P.,Alvarez, Carmen,Brown, Courtney,Chan, Tin-Yau,Doll, Ronald J.,Keertikar, Kerry,Knutson, Chad,McKittrick, Brian,Rivera, Jocelyn,Rossman, Randall,Tucker, Greg,Fischmann, Thierry,Hruza, Alan,Madison, Vincent,Nomeir, Amin A.,Wang, Yaolin,Kirschmeier, Paul,Lees, Emma,Parry, David,Sgambellone, Nicole,Seghezzi, Wolfgang,Schultz, Lesley,Shanahan, Frances,Wiswell, Derek,Xu, Xiaoying,Zhou, Quiao,James, Ray A.,Paradkar, Vidyadhar M.,Park, Haengsoon,Rokosz, Laura R.,Stauffer, Tara M.,Guzi, Timothy J.
scheme or table, p. 204 - 208 (2010/12/20)
Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability paramete
